Related Experiment Videos
On the circulating form of atrial natriuretic factor
Transactions of the Association of American Physicians
|January 1, 1985
Summary
Researchers identified the active form of atrial natriuretic factor (ANF) in plasma as a 28-amino acid peptide. This peptide effectively inhibits aldosterone secretion, with a specific shorter form proving most potent.
Area of Science:
- Endocrinology
- Molecular Biology
- Cardiovascular Physiology
Background:
- Atrial natriuretic factor (ANF) plays a role in regulating blood pressure and fluid balance.
- The precise circulating form and its biological activity require further elucidation.
Purpose of the Study:
- To isolate and sequence the immunoreactive form of ANF (IR-ANF) from plasma.
- To determine the structure-activity relationship of ANF in inhibiting aldosterone secretion.
Main Methods:
- Isolation and sequencing of IR-ANF from plasma.
- Incubation of rat zona glomerulosa cells with synthetic ANF variants.
- Structure activity relationship studies using truncated ANF peptides.
Main Results:
- The circulating form of ANF was identified as a 28-amino acid peptide (Ser 99-Tyr 126).
- This peptide demonstrated significant inhibition of basal aldosterone secretion from rat zona glomerulosa cells.
- A shorter synthetic variant (Arg 101-Tyr 126) showed comparable inhibitory activity.
- Further structure-activity studies indicated that Arg 101-Tyr 126 is the most potent form.
Conclusions:
- The 28-amino acid peptide (Ser 99-Tyr 126) is the primary circulating form of ANF.
- ANF potently inhibits basal aldosterone secretion.
- The C-terminal fragment Arg 101-Tyr 126 represents the most active moiety of ANF for aldosterone inhibition.